GPCR & Kinase Targets Conference, London, UK

March 24, 2011 - PRLog -- Background Info
Key Speakers
• Mark Bunnage, Executive Director, Medicinal Chemistry, Pfizer
• Maria Flocco, Senior Director, Lead Discovery and Structural Biology & Biophysics, Pfizer
• Guido Zaman, Senior Director GPCR and Kinases, Molecular Pharmacology Unit, Merck Sharp & Dohme
• Ulrich Wendt, Director, Structural Biology, Sanofi-Aventis
• Paul Bamborough, Section Head, Computational and Structural Chemistry, GlaxoSmithKline
• Magalie Rocheville, Investigator, GlaxoSmithKline
• Will Spooren, Project Leader, Drug Discovery, F. Hoffmann La Roche
• Leo Widler, Senior Investigator, Novartis
• Paola Casarosa, Senior Investigator, Product & Scientific Support, Respiratory Diseases, Boehringer-Ingelheim
• Lee Dawson, Director, Biopharmacology, Neurosciences Product Creation Unit, Eisai
• Trevor Howe , Research Fellow, Head of Biophysics & Structural Biology, Janssen Pharmaceutica
• Stefan Knapp, Principal Investigator, Structural Genomics Consortium, University of Oxford
• Luda Diatchenko, Chief Scientific Officer, Algynomics
• Scott DeWire, Senior Research Scientist & Co-Founder, Trevena
• Tom Klenka, Senior Business Development Manager, Drug Discovery, Merck Millipore
• Daniel Robinson, Senior Application Scientist, Schrödinger

Comprising more than 60% of all therapeutic targets, G-protein coupled receptor and kinase targets are arguably the most exciting proteins in pharmacology today. Yet, despite massive investment spanning decades, translating early research to clinical success remains frustratingly slow. New approaches are needed that acknowledge and integrate structural, functional and systems components, to accelerate time-to-market.

By attending Visiongain's GPCR and Kinase Targets conference, you will engage with leading decision makers and thought leaders, enabling you to:
• Improve the efficacy of assays to enhance 7 transmembrane and kinase drug discovery
• Incorporate improved computational models to evaluate drug-receptor interactions and allosteric modulation of downstream signalling pathways
• Evaluate gene splicing for μ-opiod drug development
• Target chemogenomic, Wnt and aneuploid-specific pathways for cancer therapy
• Employ more accurate siRNA screens to map signalling networks
• Dissect variability in chemotherapy through systems pharmacology
• Utilise developments in HTS technology to improve patient stratification
• Employ alternatives to mass spectrometry when undertaking research
• Integrate cell-signalling and systems biology insights into treatments for complex diseases
• Selectively activate and quantify beta-arrestin biased ligands for analgesia and heart disease
• Better modulate parathyroid hormone release to treat osteoporosis
• Assess pharmacotherapies in clinical development for pulmonary, neurodevelopmental and antipsychotic disorders

Who should attend?

Presidents, Chief Executive Officers, VPs, Global Heads, Chief Scientific Officers, Directors, Principal Scientists, Franchise Heads and Investigators in:
• GPCR/Kinases Research
• Structural Biology
• Molecular Pharmacology and Bioanalytical Development
• Cellular Assays
• High-Throughput/High-Content Screening Operations
• Compound Profiling
• Respiratory, CNS, Diabetes, Arthritis, Pain and Oncology Research
• Lead Generation
• In Vitro Sciences
• Pre-clinical Development
• Medicinal Chemistry
• Genomics
• Proteomics
• Bioinformatics
• Systems Biology
• Pharmacovigilance and Safety Testing
• Patient Stratification and Personalised Medicine

Associate Sponsors:
Merck Millipore
Schrödinger
Corning Life Sciences
GenScript

Media Partners:
PharmiWeb.com
BIOTECHNOLOGY EUROPE
Future Pharmaceuticals
InPharm

# # #

Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services.